

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Currently amended): A controlled release oral dosage form comprising 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt or [[solvate]] hydrate thereof, dispersed in a carrier comprising a pharmaceutically acceptable waxy mixture of glyceride-based materials, having an HLB value of 4 to 12, and an average melting point in the range of 50 to 55°C, wherein the oral dosage form comprises a stable polymorphic form of a macrogol glyceride.

Claims 2-7 (Canceled).

8. (Previously presented): An oral dosage form according to claim 1, in which the pharmaceutically acceptable waxy mixture of glyceride-based materials is waxy material obtainable by an alcoholysis/esterification reaction between a vegetable oil and a polyethylene glycol.

9. (Previously presented): An oral dosage form according to claim 8, in which the vegetable oil is a hydrogenated oil.

10. (Previously presented): An oral dosage form according to claim 9, in which the vegetable oil is hydrogenated palm oil.

Claim 11 (Canceled).

12. (Currently amended): An oral dosage form according to claim 1, in which the carrier and 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt or [[solvate]] hydrate thereof are moulded to form a tablet.

13. (Currently amended): An oral dosage form according to claim 1, in which the carrier and 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt or ~~[[solvate]]~~ hydrate thereof are filled into capsule shells to form swallow capsules.

14. (Currently amended): A method for the treatment and/or prophylaxis of diabetes mellitus, ~~conditions associated with diabetes mellitus and certain complications thereof,~~ osteoporosis, Alzheimer's Disease, psoriasis, asthma and metabolic syndrome, which comprises administering an effective amount of a the controlled release oral dosage form as claimed in claim 1 to a human or non-human mammal in need thereof.

Claim 15 (Canceled).

16. (Currently amended): A method of preparing a controlled release oral dosage form according to claim 1 which comprises dispersing 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt or ~~[[solvate]]~~ hydrate thereof, in a molten carrier comprising a pharmaceutically acceptable waxy mixture of glyceride-based materials, having an HLB value of 4 to 12, and an average melting point in the range of 50 to 55°C, filling the molten mixture into tablet moulds or capsule shells, allowing the carrier to solidify, and ~~[[optionally]]~~ thereafter maintaining the solidified dosage form at a temperature of at least 40°C, but below the melting point of the carrier, for a time sufficient to allow the macrogol glyceride to achieve a stable polymorphic form.

Claim 17 (Canceled).

18. (New): A method for the treatment of Alzheimer's Disease which comprises administering the controlled release oral dosage form as claimed in claim 1 to a human or non-human mammal in need thereof.

19. (New) The method according to claim 16, wherein the solidified dosage form is maintained at a temperature of at least 40°C, but below the melting point of the carrier, for 16-72 hours.

20. (New) The method according to claim 16, wherein the solidified dosage form is maintained at a temperature of at least 40°C, but below the melting point of the carrier, for 16 hours.

21. (New) The method according to claim 16, wherein the solidified dosage form is maintained at a temperature of at least 40°C, but below the melting point of the carrier, for 24 hours.

22. (New) The method according to claim 16, wherein the solidified dosage form is maintained at a temperature of at least 40°C, but below the melting point of the carrier, for 48 hours.